THE REBIRTH OF MATRIX METALLOPROTEINASE INHIBITORS: MOVING BEYOND THE DOGMA

The pursuit of matrix metalloproteinase (MMP) inhibitors began in earnest over three decades ago.Initial clinical trials were disappointing, resulting in a negative view of MMPs as therapeutic targets.As a better understanding of MMP simply delightful fat quarter bundle biology and inhibitor pharmacokinetic properties emerged, it became clear that

Background: This study aimed to evaluate the impact of severe asthma (SA) treatments after 12 months in achieving clinical remission (CR) within the context of the Severe Asthma Network in Italy (SANI) using the recent SANI definition of CR on treatment.Methods: CR has been defined by SANI as complete, partial, and no CR.Complete CR is defined by t